|
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer Clinical research trials and Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer. Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer  Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
For Condition: stage 3B breast cancer,stage 3C breast cancer,stage 3A breast cancer,stage 2 breast cancer
Status: Recruiting
Sponsor(s): Roger Williams Medical Center ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining chemotherapy with biological therapy in treating patients who have stage II or stage III breast cancer.
Details: OBJECTIVES: - Determine the toxic effects of sequential paclitaxel (or other taxane), doxorubicin, and cyclophosphamide followed by immunotherapy with activated T cells, interleukin-2, and sargramostim (GM-CSF) in patients with high-risk stage II or III breast cancer. - Determine the disease-free survival and overall survival of patients treated with this regimen. - Determine the immune function of patients treated with this regimen. OUTLINE: Patients are stratified according to number of positive lymph nodes (less than 4 nodes vs 4-9 nodes vs 10 or more nodes), type of taxane chemotherapy during study (paclitaxel vs other taxane), and prior treatment with 2 of 3 study chemotherapy agents (yes vs no). Patients receive doxorubicin IV on day 1 and filgrastim (G-CSF) on days 3-10 of 3 consecutive 14-day courses. Patients then receive paclitaxel or another taxane IV on day 1 and G-CSF on days 3-10 of 3 consecutive 14-day courses. Patients then receive cyclophosphamide IV on day 1 and G-CSF on days 3-10 of 3 consecutive 14-day courses. Patients who enroll after previously receiving 2 of these 3 chemotherapy drugs may receive the third. Treatment continues in the absence of disease progression or unacceptable toxicity. After recovery from chemotherapy, patients undergo peripheral blood mononuclear cell (PBMC) collection. The PBMC are treated ex vivo with monoclonal antibody OKT3 to form activated T cells (ATC). The ATC are expanded for up to 14 days in interleukin-2 (IL-2). At 3-4 weeks after PBMC collection, patients receive ATC IV over 15-30 minutes weekly for 8 weeks. Patients also receive IL-2 subcutaneously (SC) daily and sargramostim (GM-CSF) SC twice weekly beginning 3 days before the first ATC infusion and continuing until 7 days after completion of ATC therapy. Patients are followed every 3 months for 1 year and then annually thereafter. PROJECTED ACCRUAL: A total of 40-60 patients will be accrued for this study within 4-5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed stage II or III adenocarcinoma of the breast - High-risk disease - At least 4 positive lymph nodes - Fewer than 4 positive lymph nodes considered high-risk if one of the following is present: - HER2/neu-positive disease - Enlarged axillary nodes - Extra capsular extension of tumor from lymph node - Dermal lymphatic invasion - Vascular invasion - Bilateral disease - Familial breast cancer - T4 locally advanced disease - Clinically chemosensitive to prior paclitaxel (or other taxane), doxorubicin, and cyclophosphamide - No relapse after chemotherapy - No clinical evidence of brain metastases - Hormone receptor status: - Estrogen and progesterone receptor status known PATIENT CHARACTERISTICS: Age: - 18 to 60 Sex: - Female Menopausal status: - Not specified Performance status: - Karnofsky 70-100% OR - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 50,000/mm^3 - Hemoglobin greater than 8 g/dL Hepatic: - Bilirubin less than 1.5 times normal - SGOT less than 1.5 times normal Renal - Creatinine less than 1.8 mg/dL - Creatinine clearance at least 60 mL/min - BUN less than 1.5 times normal Cardiovascular: - Ejection fraction at least 45% by MUGA - No uncontrolled or significant cardiovascular disease - No myocardial infarction within the past year - No significant congestive heart failure Pulmonary: - FEV_1 at least 60% predicted - DLCO at least 60% predicted - FVC at least 60% predicted Other: - No other malignancy except curatively treated squamous cell carcinoma in situ of the cervix or basal cell skin cancer - No other serious medical or psychiatric illness that would preclude study participation - HIV negative - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - Prior standard chemotherapy with anthracyclines or combination chemotherapy involving a combination of taxanes, doxorubicin, and/or cyclophosphamide allowed Endocrine therapy: - No concurrent hormonal therapy for breast cancer - Concurrent hormonal therapy for nondisease-related conditions (e.g., insulin for diabetes) allowed - Concurrent steroids for adrenal failure, septic shock, or pulmonary toxicity allowed Radiotherapy: - Not specified Surgery: - Prior complete resection of tumor allowed Other: - Prior successful neoadjuvant therapy allowed
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LawrenceLum, Study Chair, Roger Williams Medical Center
Roger Williams Medical Center *Recruiting*
Providence, Rhode Island, 02908-4735
United States
Recruiting Lawrence Lum 401-456-2672
Additional Information:
Study ID Numbers: CDR0000068797; RWMC-0333846
Study Start Date:
Record last reviewed: August 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00022230
Other Stage 3b Breast Cancer Studies:
1. Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
2. Stress Reduction in Older Women With Stage II, Stage III, or Stage IV Breast Cancer
3. Doxorubicin and Cyclophosphamide Plus Paclitxael With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
4. Nutrition Intervention in Treating Women With Breast Cancer
5. Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
Related Studies:
Other stage 3B breast cancer Clinical Trials
Other Rhode Island Clinical Trials
Other Providence Clinical Trials
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
|
|
|
|
|
|
|
|
